Axxcess Wealth Management LLC Has $609,000 Stock Holdings in Novo Nordisk A/S $NVO

Axxcess Wealth Management LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 63.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,976 shares of the company’s stock after selling 18,864 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $609,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC raised its position in Novo Nordisk A/S by 2,101.5% during the third quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after acquiring an additional 2,274,925 shares in the last quarter. Bank of Montreal Can grew its position in shares of Novo Nordisk A/S by 101.4% in the 2nd quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock valued at $170,845,000 after acquiring an additional 1,246,467 shares during the period. DAVENPORT & Co LLC increased its stake in shares of Novo Nordisk A/S by 54.8% during the 3rd quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after purchasing an additional 935,468 shares during the last quarter. Sustainable Growth Advisers LP raised its holdings in shares of Novo Nordisk A/S by 11.7% in the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after purchasing an additional 649,390 shares during the period. Finally, Baird Financial Group Inc. lifted its stake in Novo Nordisk A/S by 42.6% in the 2nd quarter. Baird Financial Group Inc. now owns 1,476,673 shares of the company’s stock valued at $101,920,000 after purchasing an additional 441,034 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $47.43 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a market cap of $211.77 billion, a price-to-earnings ratio of 13.67 and a beta of 0.67. The stock’s fifty day moving average price is $53.77 and its two-hundred day moving average price is $53.24. Novo Nordisk A/S has a one year low of $43.08 and a one year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.63%.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent analyst reports. The Goldman Sachs Group reissued a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. CICC Research initiated coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target for the company. Citigroup assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Finally, TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $56.07.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.